Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D

Summary

Periodontal disease is a chronic inflammatory condition associated with systemic diseases, highlighting the concept of periodontal medicine. This study aims to investigate the relationship between periodontal inflammation, oral lesions, and hepatitis B+D infection, with or without bulevirtide treatment. Oral-periodontal clinical parameters and targeted inflammatory biomarkers in saliva and gingival crevicular fluid will be evaluated in three groups: patients with hepatitis B+D receiving bulevirtide, patients with hepatitis B+D not receiving bulevirtide, and healthy controls.

Eligibility

Inclusion Criteria:

* Adults (≥18 years old) capable of providing informed consent.
* For Hepatitis B+D groups: confirmed hepatitis B and D co-infection.
* Bulevirtide group: receiving bulevirtide therapy as prescribed.
* No Bulevirtide group: not receiving bulevirtide.
* For Healthy Control group: systemically healthy adults without hepatitis B or D infection.
* Willingness to undergo oral-periodontal examination, saliva and gingival crevicular fluid collection, and oral cavity photography.

Exclusion Criteria:

* Patients with other systemic diseases that could influence periodontal health (e.g., uncontrolled diabetes, autoimmune diseases).
* Patients currently receiving other experimental therapies that may affect oral or systemic inflammation.
* Pregnancy or lactation.
* Inability or unwillingness to provide informed consent.
* History of oral or periodontal surgery within the last 6 months that could affect measurements.

Conditions4

Interventions1

Related trials

• A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide — Vir Biotechnology, Inc.
• Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD) — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment — Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
• Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients — Karolinska University Hospital
• Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide — Mirum Pharmaceuticals, Inc.

Browse More Trials